A Method To Fluorescently Label The Crispr/Cas9-Grna Rnp Complexes Enables Enrichment Of Clinical-Grade Gene-Edited Primary Hematopoietic Stem Cells And Ipscs

Although proven to be an excellent method for gene editing, CRISPR/Cas9-mediated technology still has some limitations for the applications in primary hematopoietic stem cells and progenitor cells (HSPCs) as well as in human induced pluripotent stem cells (hiPSCs). Delivery of Cas9 protein in a form of ribonucleoprotein (RNP) in a complex with guide RNA (gRNA) provides a DNA free methodology, but a big hinderance of this application is that it is not possible to sort and enrich gene edited cells for further applications.